Introduction. Age is commonly considered as a factor of failure in peripheral blood stem cells (PBSC) autologous transplantation. Therefore, this treatment is usually reserved to patients aged less than 60 years. However, few data are actually available on transplantation in the elderly. The aim of this study was to evaluate the morbidity and mortality of intensive chemotherapy followed by autologous PBSC transplantation in old patients. Patients and Methods. Between January 1993 and December 1999, 125 consecutive patients received chemotherapy followed by autologous PBSC transplantation for multiple myeloma (MM) and for non Hodgkin lymphoma (NHL). According to age, patients characteristics at diagnosis and transplant are shown in the following table. For each patient we assessed severe organ toxicity (OMS grade 3 or 4) and toxic death. Results. In univariate analysis, age as continuous variable was a significant prognostic factor for transplant-related (TR) morbidity (p=.002), overall survival (OS) (p=.005) and there was a trend for TR mortality (p=.06). However, this effect of age was related to a better outcome of the youngest patients (<45 years). Rates of toxic death, severe organ toxicity and OS were similar for patients 45-60 years and over 60 which displayed similar characteristics at transplantation (Table) .
Conclusion. Age remains a poor prognostic factor for TR toxicity and post-graft survival. However, rates of toxic deaths and severe adverse events seem acceptable in the elderly when compared to younger patients usually considered for autologous transplantation. We believe that autologous PBSC transplantation should also be considered for patients older than 60. Acknowledgments to Amgen France
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Growth and endocrine late effects after stem cell transplantation (SCT) in children and adolescents C.P. Schwarze, R. Dopfer, M.B. Ranke, D. Fuchs, C. Vilser, F. Zintl, C. Bender-Götze, E. Frey, C. Peters, H. Gadner, D. Niethammer (Tuebingen, Jena, Munich, D; Vienna, A) Objective: Evaluation and treatment of late effects on growth and endocrine function in long term survivors of SCT. Patients and Methods: 410 patients treated with SCT from 1996 to 2001 were investigated. The underlying diseases were ALL 21%, AML 13%, CML 7%, MDS 8%, lymphoma 4%, aplastic anaemia 8%, neuroblastoma 11%, solid tumours 15% and others 13%. A standardised follow-up protocol was applied: Height, weight, pubertal development and body proportions were determined. Analysis of TSH, T4/fT4, LH/FSH, E2/T, IGF-I/IGFBP-3 and in addition TRH, GnRH and arginine testing was performed. Patients were examined before and 3 and 6 months, 1, 2, 3, 4 and 5 years after SCT. Results: Height (HT)-SDS before SCT was significantly, p<0.005, reduced at -0.5 SDS (median) (-4.0 to 2.7, range) versus target HT at 0.11 SDS ( -2.4 to 2.2) (N=145). HT-SDS significantly decreased further to -0.7 SDS (-5.0 to 2.9), p<0.05, and -1.0 SDS (-4.2 to 0.2), p<0.05. Individual changes in HT-SDS within 1 year ranged from -2.0 to +1.9 SDS. Longitudinal data showed that patients with ALL, AML, CML, NB lost HT-SDS, whereas patients with SAA and MDS gained HT-SDS in the follow-up period. Analysis of prepubertal growth revealed 5 growth patterns: regular growth, progressive growth failure, primary/secondary catch-up growth and initial growth failure followed by regular growth. Primary hypothyroidism was seen in 13% (23/172) before and in 19% (44/235) after SCT. Central hypothyroidism was confirmed by TRH tests before SCT in 21% (25/119) of patients with a 'normal' TSH and fT4/T4 levels in the lowest third of normal. After SCT, 65% (124/191) of patients had low fT4 and/or T4 levels and a 'normal' TSH, possibly related to hidden central hypothyroidism. Hypergonadotropic hypogonadism was detected in 22% (14/64) female (f) and 18% (26/147) male (m) patients before SCT. GnRH tests revealed a much higher rate of gonadal dysfunction: 50% f and 28% m. Longitudinal data in 28 f and 73 m patients showed normal LH/FSH levels before and elevated levels after SCT in 29% (f) and 18% (m). Conclusions: Growth failure and endocrine deficiencies are very frequent after SCT. The right diagnostic tools have to be applied to detect newly developing dysfunction. To ensure normal development each patient has to be followed individually. In cooperation of the paediatric haematologist and paediatric endocrinologist investigations must be performed according to a standardised protocol.
O291
Risk to develop Bronchiolitis obliterans with organizing pneumonia after allogeneic transplantation R. Peceny, A.H. Elmaagacli, H. Ottinger, B. Scheulen, R. Trenschel, U.W. Schaefer, D.W. Beelen (Essen, D) The occurrence of bronchiolitis obliterans with organizing pneumonia (BOOP) was prospectively compared in patients with malignant hematologic diseases who were transplanted between October 1994 and July 2001 with peripheral blood stem cells (PBSCT: n=321) or bone marrow (BMT: n=298) from HLA matched sibling (MRD: n=270), partially matched family (n=98) or matched unrelated donors (MUD: n=251). Grafts were not manipulated, and patients having received dose reduced conditioning regimens were excluded. With a median follow up of 17 months (range 0 -86 months), a total of 16 patients developed BOOP median 11 months (range 4.6 -56 months) post transplant. Four patients had no other manifestation of chronic GvHD before. Fourteen of the 16 patients were male and all patients were grafted from a female donor. Two patients died of complications of the lung disease 27 and 34 months post transplant respectively. The cumulative 7-yr-estimate of BOOP was clearly higher in male recipients of female donor grafts (22.3% ± 6.1%) compared to other gender combinations (0.6% ± 0.4%) (p < 0.0001, log-rank test). Moreover, the risk to develop BOOP was higher after PBSCT (6.6% ± 1.9%) compared to BMT (3.4% ± 1.9%) (p = 0.04). The only two female patients who developed BOOP received a PBSCT. There is no statistical influence of chronic GvHD. A trend to HLA mismatch as a risk factor in univariate analysis can be explained by a higher proportion of male patients with female donors in the group of patients grafted from partially matched family donors (58%) compared to MRDs (34%) and MUDs (15%). Multivariate analysis confirmed an independently higher relative risk (95%-confidence limits) to develop BOOP of 27.2 (6.2 -120) for male recipients of female grafts (p < 0.0001), and a borderline increased risk of 3.0 (1.0 -9.3) after PBSCT (p = 0.06). All other analyzed factors (chronic GvHD, acute GvHD, type of donor, underlying disease, donor and patient age, immune prophylaxis of GvHD) had no significant influence. In conclusion, BOOP develops after hematopoietic stem cell transplantation usually when immunosuppression is tapered with a greatly increased risk in male patients receiving female grafts with a potential further increase in risk after PBSCT. With improving results of transplantation from MUDs, female donors for male patients should be reconsidered if possible, among other reasons also because of the increased risk for the patient to develop a possibly fatal BOOP.
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Development of an EORTC questionnaire module for assessment of quality of Life during high-dose treatment
Hjermstad, O. Sezer for the EORTC Quality of Life Study Group
The objective of this project is to develop a treatment specific quality of life (QL) questionnaire module to be used in clinical trials with the EORTC core cancer questionnaire (EORTC -QLQ C30), for assessing side effects and psycho-social problems of patients undergoing high-dose treatment with haematological stem cell transplantation, including allogeneic bone marrow transplantation (BMT) and autologous BMT or peripheral stem cell transplantation (PSCT). The module is developed according to EORTC QL Group Guidelines, simultaneously in English (UK), German (Germany and Austria) and Norwegian to ensure cross-cultural applicability. The questionnaire is intended to cover treatment toxicity and complications and other QL dimensions that are reported to be important for patients during BMT treatment like psychological issues (future perspective and fear of recurrence), cognitive function, body image / appearance, sexuality /fertility and family and social problems. The questionnaire covers the peri-transplant period: i.e. the time before, during and up to 6 months after the treatment. An extensive literature review identified 124 issues relevant to cancer patients receiving high-dose treatment. The list of issues was presented to 22 health-care providers (doctors, nurses and psychologists) with experience in BMT who were asked to indicate for each issue whether it is relevant for this group of patients and to select ten most important problems. Semi-structured interviews were then conducted with 92 patients undergoing high-dose treatment. Descriptive analysis of the interviews using pre-specified criteria selected the most important issues for this group of patients. The issues were transformed into questions, resulting in a module with 50 items. The provisional module was reviewed for clarity by 11 professionals and 5 patients and then translated into German and Norwegian using rigorous forward and backward translations. The provisional module is currently being tested for acceptability and relevance in 80 patients from 4 countries. Following this phase a large international field testing will be necessary to collect data on its psychometric properties. This can be done in ongoing clinical trials of high-dose treatment in patients with haematological malignancies and solid tumours.
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Psychosocial risk factors for mortality and relapse in the first year after stem-cell transplantation (SCT): a prospective study A. Kiss, D. Biener, L. Grize, A. Gratwohl, P. Kalhs, M. Kainz, J. Passweg, R. Saner Skoda, C. Schindler, H. Greinix (Basel, CH; Vienna, A) Objectives: The somatic risk factors for one-year survival after SCT are well-established, whereas the impact of psychological factors remains to be determined. Patients and Methods: 185 adult patients (109 from Vienna, 76 from Basel) admitted for autologous (n = 101) or allogeneic (n = 84) SCT were evaluated prospectively by standardized psychometric questionnaires (HADS, POMS, MAC) prior to SCT. Disease and peritransplant risk factors were coevaluated and outcome after one year was assessed. Multivariate proportional hazard models were used to analyze different predictors of survival. Basic factors considered in each analysis were center, sex, age, disease stage, histocompatibility, CMV status, and Karnofsky score prior to transplantation. Results: Within 1 year 43 patients died (27 of them of transplantrelated causes) and 142 remained alive (but 25 of them experienced a relapse of their disease). Estimation of the baseline hazard function was stratified according to transplant type. The estimated relative risks associated with different psychological scores are summarized in the following table.
Conclusions: Psychosocial factors are independent risk factors for outcome. Helplessness and hopelessness, depression/dejection and fatigue are associated with transplant-related mortality. This is in line with recent findings from other research groups where hopelessness and helplessness in cancer patients in general and in SCT patients in particular were associated with lower survival. It is time to reconsider the role of psychosocial factors in SCT.
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Patterns of extramedullary leukemia after BMT and potential for survival
I. Cunningham (New York, USA)
The 148 published cases of clinical extramedullary relapse (EMR) after BM/SCT were analyzed. Cases of first EMR (excluding CSF) with adequate data were included. Authors were contacted for followup. The database includes 82 AML, 41 ALL, and 25 CML cases. There are 87 male and 61 female pts; 34 are <16 yrs old. Karyotypes were abnormal in 63 of 73 pts studied; no FAB subtype predominated in AML pts. Conditioning was TBI-based in 55% and busulfan-based in 37%. In 23 pts, EMR first occurred after BMT relapse, a median 7 m after treatments which included DLI+/-chemo (13), G-or GM-CSF(3), or second BMT (3). Only one such pt survived >12m, after second SCT. In the other 125 pts, EMR occurred at median 12-16 m in AML, ALL, and CML. In ALL, only 7% occurred >2 yrs after BMT, but in AML and CML, 33% of cases occurred 2-10 yr after BMT. Time from BMT to EMR was similar for pts in CR-1 (59), CR-2 (24), and advanced disease (43). Soft tissues were the principal site in AML/ALL. The most commonly reported specific sites were testis in 1/3 of males and breast in 1/3 of females. In AML, 7 of 8 adult men with testis EMR had had Bu-based transplant. The most common body area in AML was the head and neck (25%). Bone was less common in ALL/AML (<20%), than in CML (64%) and was typically associated with marrow relapse. Marrow relapsed with or after EMR in approximately 25% of ALL, 50% of AML, and 75% of CML cases. The most effective treatment was local plus systemic therapy, resulting in CR in most of 65 pts so treated. Of 28 pts given local therapy alone, only 6 survived 24 m, 4 of these had had testis relapse. Seven of 18 pts with AML/ALL treated with DLI+/-RT+/-chemo had CR of 2.5-60+ m. In total, 39 pts from case reports survived from 2 to 26+ yrs after EMR, only 2 of whom had CML. Combining and updating all available reported cases reveals that EMR post-BMT may occur: in any leukemia, and not more commonly in advanced disease; possibly more often in pts with abnormal karyotypes; and most commonly in soft tissue sites in AML/ALL, particularly breast and testis, and in bone in CML. Local and systemic therapy together has been most successful. Lengthy (2-26+yr) survival is demonstrated in at least 26% of reported cases and should encourage an aggressive approach when EMR occurs after transplant.
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T cells of recipient origin may consistently contribute to prompt recovery of Ag-specific T cell function of children given CBT D. Montagna, F. Locatelli, D Lisini, A. Moretta, S. Pagani, E. Montini, F. Bonetti, P. Grignani, A. Dehò, R. Maccario (Pavia, I) Cord blood transplantation (CBT) has been successfully used to rescue patients undergoing myeloablative therapy. As the number of Ag-specific mature T lymphocytes transferred with the graft, is significantly lower in CBT as compared with unmanipulated BMT recipients, some concern exist regarding the prompt recovery of donor-derived T cell immunity. We previously demonstrated that human cytomegalovirus (HCMV)-and candida albicans (CA)-specific CD4+ T lymphocytes of both donor and recipient origin may contribute to immune recovery after CBT. Aims of this study were to quantify the frequency of HCMV and CA-specific T cells in PBMC obtained from CBT recipients 2-3 and 12-15 months after transplant and to evaluate the contribution of recipient-and donorderived T cells to the development of immune response to these antigens. Frequency of HCMV-or CA-specific proliferating T cell precursors (PTCp) was evaluated in 9 children given CBT from either HLA-identical sibling (n=5) or from unrelated donor (n=4). Three out of 9 patients received a TBI-containing conditioning regimen. Sizeable or high frequencies of PTCp specific for HCMV (range: 1/1,900-1/25,000) or CA (range: 1/2,500-1/51,000) were found in 7 out of 9 patients both early and late after CBT. Interestingly, high frequency of HCMV-specific PTCp was documented in 5 patients in whom there was no evidence of viral reactivation. Analysis of Ag-specific T cell lines by PCR amplification of microsatellite DNA regions, demonstrated that in 4 patients 45-90% of responder lymphocytes were of recipient origin, while only a small contribution of recipient cells was found in the remaining patient. Similar ratio of donor/recipient cells was detected in CA-specific T cell lines obtained from PBMC of the same patients. Recipient cells were detected in the Ag-specific lines of patients who did not receive a TBI-containing conditioning regimen. In patients given TBI sizeable values of HCMV donorderived PTCp were found only in a patient in whom viral activation was observed. All together these findings demonstrate that: 1) TBI, as expected, impairs the possibility of recipient T cells to survive and expand after CBT, 2) Ag-specific T cells of recipient origin can play an important role in facing infectious complications in patients given CBT, without causing rejection, especially in the early post transplant period, when a primary immune response mediated by donor derived T cells is not fully developed.
O296
Thymic function after allogeneic stem cell transplantation in children M. Eyrich, D. Brügger, G. Wollny, B. Mascher, P. Bader, P. Lang, K. Schilbach, J. Greil, D. Niethammer, P.G. Schlegel (Tuebingen, Wuerzburg, D) Reconstitution of a mature T -cell compartment following allogeneic stem cell transplantation relies on the generation of naive T-cells via the thymus. However, thymic function may be adversely affected by the transplant procedure itself. In this study we assessed thymic function in 52 pediatric recipients (11 haploidentical, 19 unrelated, In conclusion, thymic function is severely affected by allogeneic stem cell transplantation, but, at least in children, recovers with time. Malignant disease is an unfavorable prognostic factor for thymic function in the first year post-transplant, probably due to heavier pretreatment. Further studies will identify factors that positively influence thymic function, e.g. higher numbers of transplanted stem cells or protection from radio-, chemotherapy induced thymic injury. An increased thymic function in the early post-transplant phase will accelerate T-cell reconstitution, thereby reducing transplant-related morbidity and mortality.
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Donor CMV serological status influences the outcome after unrelated donor stem cell transplantation; an EBMT Megafile analysis P. Ljungman, R. Brand, R. Brand, H. Einsele, F. Frassoni, D. Niederwieser, C. Cordonnier 
for the Infectious Diseases Working Party of the EBMT
Cytomegalovirus (CMV) has been one of the major causes of morbidity and mortality after allogeneic haematopoietic stem cell transplantation (HSCT). The importance of the recipient's serological status is paramount. However, the importance of the donor's serological status for outcome in CMV seropositive recipients is controversial. We analysed the influence of the donor's CMV serological status on outcome in a large cohort of patients. Data from 7018 CMV seropositive allogeneic SCT recipients reported to the European Group for Blood and Marrow Transplantation were included in the analysis. 5910 had undergone HLA-identical sibling SCT and 1108 unrelated donor SCT. Univariate and multivariate proportional hazards models
